Newsfeeds - Spark Newswire

3 minute read

Today, 2:04 PM

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis are most in need of

REGN

46 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 2:04 PM

Monday saw 825 companies set new 52-week lows.

$APE

19 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 2:04 PM

On Wednesday, 340 stocks hit new 52-week lows.

$APE

1 minute read

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger

By Vandana Singh

Today, 2:04 PM

HC Wainwright assumes coverage on Immunic Inc (NASDAQ:IMUX), a late-stage clinical biotech company developing oral small molecule inhibitors for multiple sclerosis (MS)…

IMUX

1 minute read

AstraZeneca’s COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing

By Vandana Singh

Today, 2:04 PM

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has backed using AstraZeneca Plc’s (NASDAQ:AZN)…

AZN

1 minute read

Sanofi Announced CHMP Recommended Approval of Beyfortus for Prevention of RSV Disease in Infants

By Charles Gross

Today, 2:04 PM

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

SNY

4 minute read

‘Executive Order: Declaring A Disaster In The State Of New York’

By Benzinga Newsdesk

Today, 2:04 PM

https://www.governor.ny.gov/executive-order/no-21-declaring-disaster-state-new-york E X E C U T I V E O R D E R DECLARING A DISASTER IN THE

SNY

1 minute read

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

By Vandana Singh

Today, 2:04 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) presented detailed results from the second of two Phase 3 trials (PRIME) evaluating…

REGN

1 minute read

Regeneron Highlights Dupixent (dupilumab) Late-Breaking Phase 3 Data At The EADV 2022 Congress; Says Data Show Significant Improvements In Signs And Symptoms Of Prurigo Nodularis

By Benzinga Newsdesk

Today, 2:04 PM

early three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo There are currently no approved medicines specifically indicated to treat

REGN

1 minute read

Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report

By Vandana Singh

Today, 2:04 PM

The European Union’s drugs regulator is just a few weeks away from deciding whether to approve Sanofi SA (NASDAQ:SNY) and GSK…

AZN

Latest news

Regeneron’s Dupixent Approved By FDA As First And Only Treatment Indicated For Prurigo Nodularis

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Wednesday

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger

AstraZeneca’s COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing

Sanofi Announced CHMP Recommended Approval of Beyfortus for Prevention of RSV Disease in Infants

‘Executive Order: Declaring A Disaster In The State Of New York’

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

Regeneron Highlights Dupixent (dupilumab) Late-Breaking Phase 3 Data At The EADV 2022 Congress; Says Data Show Significant Improvements In Signs And Symptoms Of Prurigo Nodularis

Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report